Sepsis Diagnostics Market Size Is Likely To Be Valued At US$ 1,630 Million By 2032

The global sepsis diagnostics market size was valued at US$ 690 Million in 2021 and is projected to grow from US$ 755 Million in 2022 to US$ 1,630 Million by 2032, exhibiting a CAGR of 8% during the forecast period.

Fact.MR, in its latest business intelligence study, depicts the nuts and bolts of the global Sepsis Diagnostics market. The report presents detailed information regarding the drivers, restraints, opportunities and trends affecting market growth.

Each segment along with its sub-segment is analyzed in terms of value and volume. Further, the report elaborates the market behavior of each vendor operating in the Sepsis Diagnostics market.

Download Sample Copy of This Report:
https://www.factmr.com/connectus/sample?flag=S&rep_id=391

Key findings of the Sepsis Diagnostics market study:

• Regional breakdown of the Sepsis Diagnostics market based on predefined taxonomy.
• Innovative manufacturing processes implemented by Sepsis Diagnostics vendors in detail.
• Region-wise and country-wise fragmentation of the Sepsis Diagnostics market to grasp the revenue, and growth outlook in these areas.
• Changing preferences among consumers across various regions and countries.
• Factors (Positive and Negative) impacting the growth of the global Sepsis Diagnostics market.

Key Companies Profiled

• BioMerieux SA
• Becton Dickinson and Company (BD)
• Thermo Fisher Scientific Inc.
• Abbott Laboratories Inc.
• Roche Holdings AG

Competitive Landscape

The global market for sepsis diagnostics is highly fragmented. The prominent companies rely on a variety of development tactics, such as broadening product portfolios, strategic mergers and acquisitions, expanding production capabilities, investing in R&D projects, and merging technical improvements into current equipment.

• Becton Dickinson and Company (BD) announced the BACTECTM Platelet Quality Control Media in 2019, earning US FDA certification to identify tainted platelet units in microbiology laboratories, blood banks, and transfusion programmes. Through a culture-based technique, the technology enables doctors to identify possibly tainted platelet donations and help lower the risk of sepsis.
• Similarly, in 2018, Thermo Fisher Scientific released the B.R.A.H.M.S PCT direct point-of-care assay blood test, which enables for the rapid identification of bacterial infection and sepsis. The test is intended to provide procalcitonin (PCT) measurement to acute care settings in order to assist quick management and exact findings for therapeutic solutions.
• T2 Biosystems Inc. has got clearance for its T2SARS-CoV-2TM Panel, a molecular diagnostic test that identifies SARS-P1 CoV-2's variant, which was recently verified in the United States. This panel has a clinical sensitivity of 95% and a specificity rate of 100%, and it produces findings in less than two hours when performed on a fully automated T2Dx® device. As the COVID-19 virus causes sepsis and mortality, these panels remain therapeutically important.

Key Segments Covered in the Sepsis Diagnostics Industry Report

• By Product :
o Blood Culture Media
o Instruments
o SAssays & Reagents

• By Method :
o Conventional
o Automated

• By Pathogen :
o Gram-Negative Bacterial
o Gram-Positive Bacterial
o Fungal
o Other Pathogens-based

• By Technology :
o Microbiology-based
o Molecular
o Immunoassays-based
o Other Technology-based

• By Region :
o North America
o Latin America
o Europe
o APEJ
o Japan
o Middle East & Africa

Get Full Access t the Complete Report:
https://www.factmr.com/checkout/391

Queries addressed in the Sepsis Diagnostics market report:

• Why are the Sepsis Diagnostics market players targeting region for increased product sales?
• What patented technologies are the players utilizing in the global Sepsis Diagnostics market?
• Which regions are displaying the fastest growth in the Sepsis Diagnostics market?
• What are the underlying micro- macroeconomic factors affecting the global Sepsis Diagnostics market?

Why choose Fact.MR?

Reports published by Fact.MR are a result of the combination of our experts and digital technologies. We thrive to provide innovative business solutions to the clients as well as tailor the reports aligning with the clients' requisites. Our analysts perform comprehensive research to offer ins and outs of the current market situation. Clients across various time zones tend to utilize our 24/7 service availability.

Contact:
US Sales Office :
11140 Rockville Pike
Suite 400
Rockville, MD 20852
United States
Tel: +1 (628) 251-1583
E-Mail: sales@factmr.com

About Fact.MR
We are a trusted research partner of 80% of fortune 1000 companies across the globe. We are consistently growing in the field of market research with more than 1000 reports published every year. The dedicated team of 400-plus analysts and consultants is committed to achieving the utmost level of our client's satisfaction.

This release was published on openPR.